Clay B. Siegall Sells 18,832 Shares of Seattle Genetics, Inc. (SGEN) Stock

Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $61.18, for a total transaction of $1,152,141.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, September 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $53.49, for a total transaction of $1,007,323.68.
  • On Monday, August 28th, Clay B. Siegall sold 25,506 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total transaction of $1,221,482.34.
  • On Monday, August 7th, Clay B. Siegall sold 10,413 shares of Seattle Genetics stock. The shares were sold at an average price of $48.91, for a total transaction of $509,299.83.

Shares of Seattle Genetics, Inc. (SGEN) opened at 63.00 on Friday. The company’s 50-day moving average is $54.50 and its 200-day moving average is $57.64. Seattle Genetics, Inc. has a 52-week low of $45.31 and a 52-week high of $75.36. The firm’s market cap is $9.01 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. The business had revenue of $108.20 million during the quarter, compared to analyst estimates of $105.92 million. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.23) EPS. Equities research analysts forecast that Seattle Genetics, Inc. will post ($1.69) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.truebluetribune.com/2017/10/15/clay-b-siegall-sells-18832-shares-of-seattle-genetics-inc-sgen-stock.html.

A number of brokerages recently commented on SGEN. Cantor Fitzgerald set a $46.00 price objective on shares of Seattle Genetics and gave the company a “hold” rating in a research note on Tuesday, October 10th. Oppenheimer Holdings, Inc. began coverage on shares of Seattle Genetics in a research note on Tuesday, October 10th. They issued a “hold” rating on the stock. Zacks Investment Research raised shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research note on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $64.00 target price on shares of Seattle Genetics in a report on Friday, October 6th. Finally, SunTrust Banks, Inc. restated a “hold” rating and issued a $45.00 target price on shares of Seattle Genetics in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $61.00.

Several institutional investors have recently made changes to their positions in the company. Neuberger Berman Group LLC lifted its holdings in shares of Seattle Genetics by 0.5% during the 1st quarter. Neuberger Berman Group LLC now owns 12,630 shares of the biotechnology company’s stock valued at $794,000 after buying an additional 59 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Seattle Genetics by 0.3% during the 2nd quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock valued at $1,640,000 after buying an additional 91 shares during the last quarter. Eqis Capital Management Inc. lifted its holdings in shares of Seattle Genetics by 0.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 26,258 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 177 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Seattle Genetics by 1.1% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock valued at $952,000 after buying an additional 200 shares during the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Seattle Genetics by 7.3% during the 1st quarter. M&T Bank Corp now owns 4,376 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 297 shares during the last quarter. Institutional investors and hedge funds own 97.63% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply